



carboplatin in recurrent 
ovarian cancer: a critical 
consideration
To the editor: Recently, Aghajanian et al. [1] have published 
the results of the independent radiologic review concerning 
the OCEANS trial [2]. This study, published in 2012, compared 
the combination gemcitabine-carboplatin (GC) plus bevaci-
zumab (BV), including BV until progression; versus GC plus 
placebo in the treatment of recurrent platinum sensitive ovar-
ian cancer (recurrence >6 months after completion of front-
line platinum based chemotherapy). The review confirmed 
the results reported in OCEANS trial, with the achievement of 
the primary endpoint. In fact, it demonstrated a statistically 
significant advantage in progression-free survival (PFS) for the 
experimental arm with GC+BV (hazard ratio [HR], 0.451; 95% 
confidence interval [CI], 0.351 to 0.580; p<0.001).
In OCEANS trial, the median PFS was 12.4 months versus 8.4 
months (p<0.001) in the GC+BV arm than in the placebo arm. 
The advantage was 4 months for the experimental arm [2]. As 
reported by the authors, the OCEANS trial is the first positive, 
randomized, phase III trial evaluating the addition of a biologic 
therapy to a standard platinum doublet in recurrent ovarian 
cancer. The platinum doublet therapy including GC was cho-
sen, as explained by the authors, based on AGO-OVAR-NCIC-
EORTC phase III study published in 2006 by Pfisterer et al. [3]. 
This study reported a statistically significant improvement in 
PFS for GC compared with carboplatin alone. The median PFS 
for the experimental arm was 8.6 months versus 5.8 months 
for the control arm (HR, 0.72; 95% CI, 0.58 to 0.90; p=0.003).
We know that this regimen is one of the treatment options 
in recurrent platinum sensitive ovarian cancer, however we 
don’t think it could be consider the standard of treatment. 
Analyzing the results of the “historical” trials concerning 
the platinum doublet therapy versus carboplatin alone in 
recurrent platinum sensitive ovarian cancer (Table 1), we can 
observe that the combinations carboplatin-paclitaxel as well 
as carboplatin-pegylated liposomal doxorubicin (PLD) give a 
statistically significant advantage in PFS of about 3 to 4 months 
(depending from the trial). The median PFS for the combina-
tion arms is 12 months [4,5]. 
Although it’s not possible to directly compare different 
studies, it’s important to underline that the median PFS of 
experimental arms from these trials, including platinum 
doublets versus carboplatin, are similar to the PFS registered 
in the GC+BV arm in the OCEANS study. So GC combination 
seems to be inferior compared to other regimens versus car-
boplatin alone. In OCEANS trial GC+BV plus BV maintenance 
versus GC+placebo the PFS was 12.4 versus 8.4, respectively. 
In previous reported historical data the PFS with platinum 
doublet regimens, as already noted, is of about 12 months.
So, considering PFS as well as overall survival results (Table 1), 
we think that the choice of GC combination in OCEANS trial 
maybe was not the best selection. BV has economical as well 
as safety implications (serious adverse events occurred in 
34.8% of patients in BV arm), so we should consider when it 
can be really useful in improving patients’ outcome.
We think that probably other combinations could be more 
effective in improving PFS in recurrent platinum sensitive 
ovarian cancer. Moreover, as already reported by Tomao et al. 
[6], we agree about the doubt concerning the lack of CA-125 
evaluation to assess progression disease. We think that marker 
evaluation in recurrent ovarian cancer, as indicated in previous 
studies and by the Gynecologic Cancer Intergroup, is essential 
in the management of recurrent ovarian cancer, especially in 
trials including maintenance therapy. Assessing progression 
disease only with radiological/response evaluation criteria in 
solid tumors (RECIST) criteria is debatable.
Our doubts about OCEANS trial results are confirmed in Na-
tional Comprehensive Cancer Network American guidelines, 
version 2.2014. In fact, the combination GC+BV is a category 
2B recommendation (that means “based upon lower-level evi-
dence”). As reported in guidelines, this is because there is less 
consensus among the NCCN panel that this intervention is 
appropriate. Panel members fell other combination regimens 
are more beneficial and effective than those with BV.
We know that European Medicines Agency approved the 
combination GC+BV in platinum sensitive relapsed ovarian 
cancer in patients who have not previously received BV. Ac-
cording to previous considerations we express some doubts 
about the effectiveness of this regimen or better we believe 
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that more strong evidences about BV efficacy in this setting 
and about the best chemotherapy to combine with it should 
be provided.
Nowadays with the introduction of BV in front line therapy, 
we need further studies to define the better treatment 
option in platinum recurrent ovarian cancer, to define which 
patients could benefit from BV based therapy, and to choose 
the better strategy based on time of recurrence, considering 
new available options for platinum partially sensitive relapsed 
ovarian cancer patients [7].
CONFLICT OF INTEREST 
No potential conflict of interest relevant to this article was 
reported.
REFERENCES
 1. Aghajanian C, Goff B, Nycum LR, Wang Y, Husain A, Blank S. 
Independent radiologic review: bevacizumab in combination with 
gemcitabine and carboplatin in recurrent ovarian cancer. Gynecol 
Oncol 2014;133:105-10. 
 2. Aghajanian C, Blank SV, Goff BA, Judson PL, Teneriello MG, Husain 
A, et al. OCEANS: a randomized, double-blind, placebo-controlled 
phase III trial of chemotherapy with or without bevacizumab 
in patients with platinum-sensitive recurrent epithelial ovarian, 
primary peritoneal, or fallopian tube cancer. J Clin Oncol 
2012;30:2039-45. 
 3. Pfisterer J, Plante M, Vergote I, du Bois A, Hirte H, Lacave AJ, et 
al. Gemcitabine plus carboplatin compared with carboplatin in 
patients with platinum-sensitive recurrent ovarian cancer: an 
intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC 
GCG. J Clin Oncol 2006;24:4699-707. 
 4. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, 
Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy 
versus conventional platinum-based chemotherapy in women 
with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. 
Lancet 2003;361:2099-106. 
 5. Alberts DS, Liu PY, Wilczynski SP, Clouser MC, Lopez AM, Michelin 
DP, et al. Randomized trial of pegylated liposomal doxorubicin 
(PLD) plus carboplatin versus carboplatin in platinum-sensitive (PS) 
patients with recurrent epithelial ovarian or peritoneal carcinoma 
after failure of initial platinum-based chemotherapy (Southwest 
Oncology Group Protocol S0200). Gynecol Oncol 2008;108:90-4. 
 6. Tomao F, Tomao S, Panici PB. Improvement in progression-free 
survival in OCEANS bevacizumab arm: a critical point of view. J Clin 
Oncol 2013;31:166-7. 
 7. Sehouli J, Alfaro V, Gonzalez-Martin A. Trabectedin plus pegylated 
liposomal doxorubicin in the treatment of patients with partially 
platinum-sensitive ovarian cancer: current evidence and future 
perspectives. Ann Oncol 2012;23:556-62. 
Sara Giovannoni, Patrizia Trenta
Oncology Unit B, Department of Radiology, Oncology and 
Human Pathology, Policlinico Umberto I, Sapienza University 
Rome, Rome, Italy
Correspondence to Sara Giovannoni 
Oncology Unit B, Department of Radiology, Oncology and Human 
Pathology; Policlinico Umberto I, Sapienza University Rome, Viale Regina 
Elena 324, 00161 Rome, Italy. E-mail: sagiovannoni@gmail.com
http://dx.doi.org/10.3802/jgo.2014.25.4.355
Table 1. Phase III trials. Recurrent platinum sensitive ovarian cancer
Trial Chemotherapy
Progression-free survival (mo) Overall survival (mo)
Median p-value Median p-value
Pfisterer et al. [3], AGO/OVAR CBDCA 5.8 0.031 17.3 0.73
CBDCA+GEM 8.6 18
Parmar et al. [4], ICON4 Platinum based 9 <0.001 24 0.023
PTX+CBDCA 12 29
Alberts et al. [5], SWOG CBDCA 8 0.02 18 0.02
CBDCA+PLD 12 26
CBDCA, carboplatin; GEM, gemcitabine; PLD, pegylated liposomal doxorubicin; PTX, paclitaxel.
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